Harry interviews Andrew A. Radin, co-founder and CEO of twoXAR, an Artificial Intelligence driven drug discovery startup that unifies disparate data to identify potential disease treatments.
JP Lee, managing director of SoftBank Ventures, will join Andreessen Horowitz general partner Vijay Pande on the twoXAR board of directors. Palo Alto, California-based twoXAR reached this next stage of growth thanks to $3.4 million in seed funding it picked up in 2014 in part from Andreessen Horowitz.
Palo Alto, CA-based twoXAR has developed a drug discovery computing platform that it says is faster, less expensive, and more accurate than traditional laboratory approaches. The company claims it can identify drug candidates for testing “in weeks rather than years.” The company adds that the technology has yielded potential drugs in a wide range of diseases including liver cancer, rheumatoid arthritis, and type 2 diabetes.
Traditionally, building a portfolio of drug programs requires hundreds of millions of dollars and takes many years in the biopharmaceutical industry. The convergence of available biomedical data, affordable cloud computing, and advances in algorithms is now enabling companies to build these drug portfolios for an order of magnitude less money and in a fraction of the time it traditionally takes. This is precisely what twoXAR is doing.
twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, announced today that it has raised $10 million in Series A financing led by SoftBank Ventures, a SoftBank Group early stage venture capital arm.
